ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
16 Octobre 2023 - 7:00AM
Business Wire
The late-breaking clinical results session
will reveal exclusively RACERS’ Phase 2a clinical data in sepsis
that met primary and secondary endpoints
Two additional abstracts have been selected
for presentation at the 2023 Kidney Week: an oral presentation on
how CER-001 modulates ischemia/reperfusion injury in kidney grafts
and a poster on the action of CER-001 in brain fog associated with
acute kidney injury
Access here the full press release
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only recombinant human apoA-1, announces that the Company’s
Phase 2b RACERS study in sepsis has been selected as a
late-breaking clinical trial poster presentation at the 2023
American Society of Nephrology Annual Meeting taking place November
2-5, 2023 in Philadelphia, Pennsylvania.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new apoA-I vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231015382226/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
